Andrea Ruth Hagemann MD
Gynecologic Oncology
Gynecologic Oncology
Join to View Full Profile
4921 Parkview Pl# DvSaint Louis, MO 63110
Phone+1 314-362-3181
Fax+1 314-362-2893
Dr. Hagemann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2008 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Obstetrics and Gynecology, 2004 - 2008- Washington University in St. Louis School of MedicineClass of 2004
Certifications & Licensure
IL State Medical License 2020 - 2026
MO State Medical License 2011 - 2026
PA State Medical License 2008 - 2012
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Start of enrollment: 2010 Aug 01
- Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma Start of enrollment: 2016 Jan 01
- Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome Start of enrollment: 2021 Apr 09
Publications & Presentations
PubMed
- Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer.Angela Schab, Amanda Compadre, Rebecca Drexler, Megan Loeb, Kevin Rodriguez
The Journal of Clinical Investigation. 2025-07-01 - OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed...Premal H Thaker, Debra L Richardson, Andrea R Hagemann, Robert W Holloway, Mark Reed
Gynecologic Oncology. 2025-06-01 - Integration of a lifestyle modification intervention for women with overweight and obesity in a gynecologic oncology practice.David H Morris, Alison Kosmacki, Leah Tolby, Christine Marx, Jessica Vanderlan
Gynecologic Oncology. 2025-05-01
Journal Articles
- Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian CancerIan S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
- Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous CancerIan S Hagemann, Carolyn K McCourt, Matthew A Powell, Premal H Thaker, David G Mutch, Katherine C Fuh, Andrea R Hagemann, Clinical Cancer Research
Press Mentions
Medical Students Celebrate Their Teachers, MentorsNovember 19th, 2019
Case Series Do Gynecologic Oncology Patients with Severely Diminished Renal Function and Urinary Tract Obstruction Benefit from Ureteral Stenting or Percutaneous Nephrostomy?May 12th, 2019
$11.6 Million Grant Supports Innovative Research in Endometrial Cancer – Washington University School of Medicine in St. LouisSeptember 7th, 2023- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
